• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • LinkedIn
  • YouTube
  • Instagram
  • X
  • Contact Us
  • Clinical Trials
  • Careers
  • Investors
Insmed Insmed

Insmed

  • Company

    Company

    Get to know Insmed, see what drives us, and learn how we’re building a company where people come first.

    Learn about our company

    • Culture
    • What Guides Us
    • Management Team
    • Board of Directors
    • Partnerships

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients

    Patients

    See how we collaborate with patients to shape every step of our shared journey.

    Learn about our
    commitment to patients

    • Disease Areas
    • Patient Advocacy & Resources
    • Patient Access

    Current Clinical Trials

    Learn more about our clinical trials or find a relevant trial near you.

    See if you may qualify

  • Science

    Science

    Discover the innovative science that fuels our commitment to delivering breakthroughs.

    Learn about our science

    • Pipeline
    • Areas of Innovation
      • Gene Therapy with Targeted Delivery
      • Protein Deimmunization
      • RNA End-Joining
      • Synthetic Rescue
    • Investigator-Initiated Research
    • Grants & Funding
  • Therapies

    Therapies

    Learn about our therapies

    • ARIKAYCE®
    • BRINSUPRI®
  • Responsibility

    Responsibility

    See how we’re continuing to advance science sustainably and ethically.

    Learn about our
    commitment to responsibility

    • Patients we serve
    • Innovation we deliver
    • People we empower
    • Communities we strengthen
    • Planet we protect
    • Governance we uphold
      • Global Healthcare Compliance
      • Policies & Disclosures

    Responsibility Report

    Our Responsibility Report reflects the culture and purpose we live by every day. We are committed to reporting annually on our progress and commitments.

    Learn more

  • Company
    • Company
    • Culture
    • What Guides Us
    • Management Team
    • Board of Directors
    • Partnerships
  • Patients
    • Patients
    • Disease Areas
    • Patient Advocacy & Resources
    • Patient Access
  • Science
    • Science
    • Pipeline
    • Areas of Innovation
      • Gene Therapy with Targeted Delivery
      • Protein Deimmunization
      • RNA End-Joining
      • Synthetic Rescue
    • Investigator-Initiated Research
    • Grants & Funding
  • Therapies
    • Therapies
    • ARIKAYCE®
      BRINSUPRI®
  • Responsibility
    • Responsibility
    • Patients we serve
    • Innovation we deliver
    • People we empower
    • Communities we strengthen
    • Planet we protect
    • Governance we uphold
    • Global Healthcare Compliance
    • Policies & Disclosures
  • Investors
  • Press Releases
  • Events & Presentations
  • Financials & Filings
    • Earnings Results
    • Annual Reports
    • SEC Filings
  • Corporate Governance
  • Responsibility Reports
  • Resources
    • Stock Information
    • Investor FAQs
    • Analyst Coverage
    • Email Alerts

Press Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • Jun 4, 2019
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Read more

  • May 24, 2019
    Insmed Announces Closing of Public Offering of Common Stock

    Read more

  • May 21, 2019
    Insmed Announces Pricing of Public Offering of Common Stock

    Read more

  • May 20, 2019
    Insmed Announces Proposed Public Offering of Common Stock

    Read more

  • May 20, 2019
    New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease
    --ARIKAYCE Plus Guideline-Based Therapy (GBT) Associated with Significantly Higher Rates of Sustained Culture Conversion on Therapy and Durable Culture Conversion Three Months Post-Treatment Compared with GBT Alone--

    Read more

  • May 7, 2019
    Insmed Reports First Quarter 2019 Financial Results and Provides Business Update
    -- ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales $21.0 Million for the First Quarter of 2019 --

    Read more

  • Apr 30, 2019
    Insmed to Host First Quarter 2019 Financial Results Conference Call on Tuesday, May 7, 2019

    Read more

  • Apr 9, 2019
    Insmed Granted Additional U.S. Patent For ARIKAYCE® (amikacin liposome inhalation suspension), Strengthening Brand's Global Patent Portfolio
    --Patent is 10th Issued in the U.S. for ARIKAYCE and Second Extending Patent Protection into 2035--

    Read more

  • Apr 8, 2019
    Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch
    --ARIKAYCE Preliminary U.S. Net Product Sales Approximately $21.0 Million for the First Quarter of 2019--

    Read more

  • Apr 2, 2019
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Read more

Show 5102550100 per page
  • «
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • …
  • 78
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Sign Up

Investor Presentation

View the latest Insmed Investor Presentation

Download

Footer

Insmed

LinkedIn YouTube Instagram X

Terms of Use Privacy Policy California Notice at Collection U.S. Consumer Health Data Privacy Policy Your Privacy Choices

© 2026 Insmed Incorporated. All Rights Reserved.

You are now leaving Insmed's website.

Insmed does not control, review, or endorse third-party websites, and you agree that Insmed is not responsible for the content of the website you are about to enter.